Test PPT
•Download as PPT, PDF•
0 likes•24 views
The document discusses standards and requirements for biospecimen research including developing standard operating procedures, scientific standards, standardized reference sets, and collecting biospecimens from various customer types such as advocacy groups, academia, and industry for large scale projects, clinical trials, and correlative studies. It also mentions specimen processing, quality control, informatics, organ transplants, rapid autopsies, and delivery to customers.
Report
Share
Report
Share
Recommended
Julie Corfield
The document discusses collaboration in biobanking to support pharmaceutical R&D activities. It notes that R&D costs are high and innovation is needed. Biobanks can help by providing samples for research into diseases. The document describes AstraZeneca's global biobank network and examples of collaborations on disease-specific biobanks for conditions like rheumatoid arthritis and COPD. It argues that more collaboration is needed through standards, infrastructure, addressing ethical issues, and meeting customer needs to sustain R&D activities.
Core F - Dr. Connell Russo
The In Vitro Screening (IVS) Core will assess the antimicrobial efficacy of compounds provided by Projects 1-5 using efficient medium throughput screening. The IVS Core will determine MIC90 values using a 96 well plate assay and confirm compound purity. Specialized assays will also be available to evaluate compounds for potential cytotoxicity, inhibition of metabolic activity, and inhibition of cell proliferation using mammalian cells. The IVS Core will utilize various infection models and drug analysis techniques. Data will be stored using Collaborative Drug Discovery software. The team has over 65 years of combined experience in bacterial drug discovery and analysis of antibiotic susceptibility and resistance.
Developing a Test for COVID-19 at Michigan Medicine
Developing a Test for COVID-19 at Michigan MedicineUniversity of Michigan Department of Emergency Medicine
This document summarizes the development of COVID-19 testing at Michigan Medicine. It discusses the process of obtaining FDA approval or emergency use authorization for tests, challenges in developing and validating new tests, and lessons learned from expanding testing capacity. Initial efforts focused on verifying and validating tests from CDC protocols and commercial vendors. Over time, testing was expanded to more patients using high-throughput and rapid turnaround time assays. Challenges included shortages of collection kits and regulatory barriers, while lessons highlighted the need for better integration between clinical labs, public health, and industry in response to emerging diseases.Accomplishments V Shyamala
Venkatakrishna Shyamala has extensive experience in molecular diagnostics and research and development. She has held leadership roles at several companies developing molecular diagnostic tests and was involved in the development, validation, and implementation of alternative nucleic acid tests for HCV and WNV screening at Chiron Corporation. She has also consulted for Novartis Diagnostics and contributed to establishing standards for molecular diagnostic methods through her work with CLSI.
V Shyamala Resume
This document provides a summary of Venkatakrishna Shyamala's background and experience in molecular diagnostics and blood testing spanning over 25 years. It includes information on her educational background, work experience at various biotech companies focusing on assay development and next generation technologies, areas of expertise, selected publications, and extra mural funding. She has consulted for various companies and organizations, and served on committees providing expertise in molecular methods for clinical testing.
Local Biotechs: Unleash the Power
This document provides an overview of local biotech companies in Hong Kong Science and Technology Parks (HKSTP). It summarizes 15 diagnostic companies from local universities in HKSTP, including those from Chinese University (CUHK), University of Hong Kong (HKU), University of Science and Technology (UST), and Hong Kong Baptist University (HKBU). It highlights several local high-fliers, including Prof. Dennis Lo from CUHK who founded Arbele and Xcelom, and Prof. Michael Yang from CityU who founded Multigene Diagnostics and Genetel Pharmaceuticals. It also discusses trends in personalized medicine, obstacles, and examples of novel designs and a start-up biotech company to illustrate
Dr AB Pant- In Vitro Studies in GLP Setup
This document discusses the requirements and procedures for conducting in vitro studies according to Good Laboratory Practice (GLP). It outlines prerequisites like specialized infrastructure, training, and waste disposal arrangements. Prior requirements include justifying and characterizing the test system, and ensuring authenticity through identification, stability, functionality, and purity. Other responsibilities involve procedures for cryopreservation, maintaining sterility, and separating different studies and test systems. Proper documentation of all batch records, equipment maintenance, and cell origins must also be followed.
Church GeT-RM
This document discusses the GeT-RM Project and Browser, which provides a resource for clinical testing laboratories to submit and analyze genomic variant call data. It lists the project team members and participating laboratories. The GeT-RM Browser allows laboratories to analyze variant call concordance and validation data across different sequencing platforms. Looking forward, the project aims to improve analysis tools and the browser interface with features like consensus genotype sets, investigation of discordant regions, and improved gene navigation.
Recommended
Julie Corfield
The document discusses collaboration in biobanking to support pharmaceutical R&D activities. It notes that R&D costs are high and innovation is needed. Biobanks can help by providing samples for research into diseases. The document describes AstraZeneca's global biobank network and examples of collaborations on disease-specific biobanks for conditions like rheumatoid arthritis and COPD. It argues that more collaboration is needed through standards, infrastructure, addressing ethical issues, and meeting customer needs to sustain R&D activities.
Core F - Dr. Connell Russo
The In Vitro Screening (IVS) Core will assess the antimicrobial efficacy of compounds provided by Projects 1-5 using efficient medium throughput screening. The IVS Core will determine MIC90 values using a 96 well plate assay and confirm compound purity. Specialized assays will also be available to evaluate compounds for potential cytotoxicity, inhibition of metabolic activity, and inhibition of cell proliferation using mammalian cells. The IVS Core will utilize various infection models and drug analysis techniques. Data will be stored using Collaborative Drug Discovery software. The team has over 65 years of combined experience in bacterial drug discovery and analysis of antibiotic susceptibility and resistance.
Developing a Test for COVID-19 at Michigan Medicine
Developing a Test for COVID-19 at Michigan MedicineUniversity of Michigan Department of Emergency Medicine
This document summarizes the development of COVID-19 testing at Michigan Medicine. It discusses the process of obtaining FDA approval or emergency use authorization for tests, challenges in developing and validating new tests, and lessons learned from expanding testing capacity. Initial efforts focused on verifying and validating tests from CDC protocols and commercial vendors. Over time, testing was expanded to more patients using high-throughput and rapid turnaround time assays. Challenges included shortages of collection kits and regulatory barriers, while lessons highlighted the need for better integration between clinical labs, public health, and industry in response to emerging diseases.Accomplishments V Shyamala
Venkatakrishna Shyamala has extensive experience in molecular diagnostics and research and development. She has held leadership roles at several companies developing molecular diagnostic tests and was involved in the development, validation, and implementation of alternative nucleic acid tests for HCV and WNV screening at Chiron Corporation. She has also consulted for Novartis Diagnostics and contributed to establishing standards for molecular diagnostic methods through her work with CLSI.
V Shyamala Resume
This document provides a summary of Venkatakrishna Shyamala's background and experience in molecular diagnostics and blood testing spanning over 25 years. It includes information on her educational background, work experience at various biotech companies focusing on assay development and next generation technologies, areas of expertise, selected publications, and extra mural funding. She has consulted for various companies and organizations, and served on committees providing expertise in molecular methods for clinical testing.
Local Biotechs: Unleash the Power
This document provides an overview of local biotech companies in Hong Kong Science and Technology Parks (HKSTP). It summarizes 15 diagnostic companies from local universities in HKSTP, including those from Chinese University (CUHK), University of Hong Kong (HKU), University of Science and Technology (UST), and Hong Kong Baptist University (HKBU). It highlights several local high-fliers, including Prof. Dennis Lo from CUHK who founded Arbele and Xcelom, and Prof. Michael Yang from CityU who founded Multigene Diagnostics and Genetel Pharmaceuticals. It also discusses trends in personalized medicine, obstacles, and examples of novel designs and a start-up biotech company to illustrate
Dr AB Pant- In Vitro Studies in GLP Setup
This document discusses the requirements and procedures for conducting in vitro studies according to Good Laboratory Practice (GLP). It outlines prerequisites like specialized infrastructure, training, and waste disposal arrangements. Prior requirements include justifying and characterizing the test system, and ensuring authenticity through identification, stability, functionality, and purity. Other responsibilities involve procedures for cryopreservation, maintaining sterility, and separating different studies and test systems. Proper documentation of all batch records, equipment maintenance, and cell origins must also be followed.
Church GeT-RM
This document discusses the GeT-RM Project and Browser, which provides a resource for clinical testing laboratories to submit and analyze genomic variant call data. It lists the project team members and participating laboratories. The GeT-RM Browser allows laboratories to analyze variant call concordance and validation data across different sequencing platforms. Looking forward, the project aims to improve analysis tools and the browser interface with features like consensus genotype sets, investigation of discordant regions, and improved gene navigation.
Updates to VSClinical ACMG Guidelines & a Tour of Cancer Annotation Sources
Earlier this year we launched our latest product VSClinical featuring workflow support for the ACMG guidelines with advanced automation capabilities and per-criteria recommendations. It has been amazing to watch the adoption of this product in labs doing both germline and in some cases cancer variant interpretation. Our latest VarSeq 2.1 release demonstrates our approach to iterative product improvements based on our committed relationship with our customers and includes numerous enhancements to VSClinical.
In this webcast, we cover the new and updated capabilities that can add value to your genetic testing workflows as well as review the VarSeq workflow support somatic variant interpretation in tumors by leveraging our cancer-specific annotations sources. In this webcast, we:
-Demonstrate the new “Consortium Classification” support in VSClinical to have an additional ClinVar-like annotation source added to the automated and interactive ACMG scoring process.
-See how previous interpretations are integrated into your VSClinical analysis, whether they are for the current variant or are just in the genomic neighborhood.
-Cover the additional “Lookup in PubMed” variant search feature for finding supporting studies that may provide functional or clinical evidence for a variant.
-See in action the new ACMG Auto Scoring based templates for trio analysis and gene panel tests.
-Review somatic variant filtering and prioritizing in VarSeq and the updates to relevant public annotation sources including CiVIC, ICGC and a new and available to license COSMIC v86!
Liquid biopsies- Learn about the newer ways of diagnosing malignancy
Liquid biopsies are innovative methods of detecting serious conditions at its very onset. It's now in its developmental stage. Some of the liquid biopsies are approved by the FDA of United States and are spreading across the world. Let's hope that this opens the field of easier, earlier and more economic detection of diseases.
PhoRank 2.0: Improved Phenotype-Based Gene Ranking in VarSeq
When performing variant analysis on whole exome or large gene panels, clinicians must sort through thousands of variants to determine which variants are most likely to be associated with the patient’s phenotypes. To assist with this process, we have implemented the PhoRank algorithm, which incorporates phenotypic associations to highlight the most relevant genes with potentially damaging variants. PhoRank 1.0 supports researchers leveraging all possible gene-disease associations by traversing multiple gene and pathway ontologies. Recent papers have demonstrated new techniques that have improved ranking performance in a clinical context. We have incorporated these new strategies into PhoRank 2.0: providing better ranking and improved computational performance for most clinically diagnostic and testing scenarios. Join us in this webinar as we cover:
Utility of gene ranking in genetic testing
Scenarios that warrant the use of PhoRank 2.0
New ranking strategies provided by recent papers
Benchmarks of PhoRank 2.0 on published datasets
Golden Helix provides a comprehensive solution for NGS testing labs to perform best practice guidelines such as ACMG and AMP. Our gene ranking methods provide a vital role in scaling tests to large gene panels and exomes. Please join us as we review the testing workflow and how this significant update to our gene ranking algorithm fits into the testing workflow.
Wu xi apptec lab testing division overview 2016
WuXi AppTec's Laboratory Testing Division is a large growth engine that provides integrated testing solutions to support drug development, clinical diagnostics, and medical device testing. It has over 1,600 employees across sites in China and the US. The division offers a full range of preclinical and clinical services, including CMC development, safety and efficacy testing, bioanalysis, and biomarker analysis. It also has platforms for in vitro diagnostics and medical device testing. The division aims to transform scientific ideas into healthcare products to better serve patients.
Aug2013 GeT-RM project and genome browser
This document summarizes the GeT-RM Project and Browser, which collects and analyzes genetic variant data submitted by various clinical and research laboratories. It describes the project team members and submitting labs. It provides information on the types and platforms of tests conducted, validation methods used by labs, read count distributions, and gene-level concordance calculations. It also outlines future analyses, improvements to the browser, and inclusion of paralogous sequence variant data.
Golden Helix's End-to-End Solution for Clinical Labs
In this webcast, we provide an overview of our complete end-to-end clinical stack. Initially, we walk through our powerful secondary analysis pipeline which allows you to call SNVs and CNVs. We then demonstrate how various types of CNVs are called and discuss metrics that express the confidence associated with each call.
From there, we show you our powerful tertiary analysis capabilities for gene panels, exome, and whole genome data. We show how our users can move seamlessly from the variant interpretation stage to a clinical report. Lastly, we demonstrate how our genetic data warehouse, VSWarehouse, can be used in the clinic. We also demonstrate various use cases and show how a comprehensive assessment catalog can be utilized to ensure consistent analysis across multiple labs.
We hope you enjoy our first presentation on Golden Helix's entire end-to-end solution for clinical labs!
Introducing VSClinical: Streamlining ACMG Variant Interpretation Guidelines
We have seen the widespread adoption of VarSeq in the clinic. It is chosen for its versatility and flexibility as well as the extensive catalog of annotations provided by Golden Helix. In a genetic testing scenario, VarSeq provides the annotated and filtered list of high-quality variants to that are ready for the user to classify and interpret.
In this webcast, we introduce a new product VSClinical that enables the interpretation of variants following the ACMG Guidelines. By incorporating new algorithms and annotation sources, detailed variant scoring and classification can occur right within VarSeq and without the need for additional external tools or resources.
Join us to see these upcoming capabilities:
Streamline the ACMG scoring guidelines with supportive recommendation and incorporated historical precedence
See the new algorithms behind the automated recommendation algorithm, and how they provide various levels of evidence
Drill down to an unprecedented level of supporting evidence for mutation hot spots, splice site predictions, and related clinical assertions
Build your own lab practices around new capabilities of blinded interpretations, collaborative interpretation review and detailed audit logs for CLIA compliance
Finalize your interpretation for a sample and compose the clinical report with the classified variants and their interpretation
In combination, this can be a game-changer for any clinical lab looking to improve their efficiency and reproducibility of the most complex step in the genetic testing workflow.
Introducing Drugs & Trials for Cancer Diagnostics
When interpreting a variant using the AMP/ASCO guidelines for somatic variant interpretation, clinicians must determine whether the variant can be considered a biomarker that affects clinical care by predicting sensitivity, resistance, or toxicity to a specific therapy. Such a determination requires the investigation of multiple evidence sources, including clinical trials, FDA approved therapies and peer-reviewed studies. Unfortunately, strong evidence linking specific genetic biomarkers to FDA-approved therapies only exists for a small number of cancers. Thus, most variants require an exploration of clinical practice guidelines, peer-reviewed literature, and large-scale cancer mutation databases to effectively assess the clinical significance of a given mutation.
This webcast explores this new incorporation of Drugs & Trials Annotations in VSClinical's AMP Workflow covering:
Identification of relevant clinical evidence for drug sensitivity and resistance based on patient biomarkers and tumor type
Review of clinical trial information including inclusion criteria, trial status, and contact information
Management of citations associated with relevant, targeted therapies
Evaluation of a biomarkers clinical evidence tier based on available evidence for drug sensitivity and resistance
Pre-Clinical Strategies for Evaluation and Validation of Percutaneous Heart V...
Pre-Clinical Strategies for Evaluation and Validation of Percutaneous Heart V...marcus evans Network
Chip Corso, Edwards Lifesciences, Speaker at the marcus evans Medical Device R&D Summit Fall 2011, Amelia Island, Florida, delivered his presentation on Pre-Clinical Strategies for Evaluation and Validation of Percutaneous Heart ValvesWhat to Expect During an HRPP Quality Improvement Unit Routine Site Visit : P...
This document discusses preparing for and undergoing a routine site visit from the UCSF HRPP Quality Improvement Unit (QIU). It outlines what studies undergo these visits, how to schedule and prepare records, what to expect during the 3-hour visit, common findings from past visits, and resources for questions. The QIU conducts routine monitoring of studies that are greater than minimal risk and have been active for 5 years or less. Preparing includes assembling regulatory documents, reviewing records using the QIU's form, and addressing any issues found. The visit involves discussion, record review, and feedback on recommendations or significant findings.
ZhenWuCV2016
This document summarizes the qualifications and experience of Zhen Wu, including over 20 years of experience in biomedical research with expertise in biologics drug development and bioanalytical assays. Wu has worked in both the biotechnology/pharmaceutical industry and academia, leading multiple biologics projects involving antibody, fusion protein, and oligonucleotide therapeutics. Wu's experience includes developing and validating bioanalytical assays, managing outsourced studies, conducting preclinical research, and providing support for IND submissions and clinical trials.
Reduce Turn-Around with Enhanced Cancer Annotations and CancerKB Updates
Annotation sources are constantly evolving, sometimes quite literally overnight. This is especially true in the case of cancer databases. These ever-evolving annotation sources, coupled with increasing research publications, make it difficult to do variant analysis with up-to-date scientific knowledge. With the resources available to an individual clinician or single lab, this may even prove impossible. Fortunately, VSClinical provides access to the most current clinical annotation sources - automating scoring and interpreting variants according to the most recent ACMP and AMPO guidelines. This includes many fast-changing sources such as ClinVar and COSMIC, as well as expert-curated reviews of literature and the latest drug-labeling from regulatory bodies.
In this webcast, we demonstrate the automation of a cancer workflow with enhanced cancer annotations for somatic and germline cancer variants:
- Golden Helix’s own CancerKB database has been updated to include new interpretations for genes and biomarkers with AMP Tier Level I evidence for drug sensitivity, resistance, diagnostic, and prognostic information.
- We feature a new Golden Helix curated annotation source that automates the scoring of TP53 variants with the special rule specifications by ClinGen’s TP53 Expert Panel.
- The ClinGen Expert Curated Interpretation of Variants has always been available as an annotation source for VarSeq projects, but now the expert comments and interpretations can automatically be pulled into VSClinical and used for clinical reports.
This webcast walks through a hematological-focused cancer workflow that shows off the enhanced cancer annotations and CancerKB updates!
Processing Hereditary Cancer Panels in VarSeq
Processing variants related to cancer is an incredibly critical process and a primary goal is to not only assess the variants rapidly but also accurately. A major improvement to cancer panel workflow efficiency is to utilize VarSeq for variant filtering, annotating, and interpretation. In this webcast we’ll cover some important quality assurance capabilities VarSeq provides, multiple approaches to build targeted panels, how to access/utilize numerous cancer annotations, and finally work through the ACMG guideline process on the selected germline cancer variants. The overall goal is to cover the basics of building the cancer gene panel project template so that it can be used routinely in high throughput environments.
How to Get Published in a Scientific Journal
Dr. Edward Kai-Hua Chow, JALA Associate Editor/Asia and National University of Singapore, shares his SLAS2013 JALA and JBS Authors Workshop presentation. Learn more about these leading peer-reviewed journals, and then see Ed's tips for publication beginning on slide 16.
Creating & Managing Reusable Gene Lists with VSClinical
Golden Helix supports performing repeatable clinical workflows designed to meet the needs of your lab's clinical genetic tests. A critical component of any genetic test is the reporting of clinically significant genes and the ability to limit interpretations to a predefined set of test-specific genes. This webinar will cover the upcoming “Managed Gene List” feature of VarSeq and VSClinical which enables the defining and re-use of gene lists outside of individual product templates.
The community has stepped up to provide disease-specific gene lists that are validated and well-researched for specific genetic disorders. In this webinar, we will discuss how these gene lists can be incorporated into your VSClinical workflows and we will demonstrate how these gene lists can be modified to meet the specific needs of your lab.
Things you will learn:
How to manage gene lists in a single location and use them for filtering, annotation, and reporting
How to use the recently released ACMG Secondary Findings v3.0 list for reporting incidental findings
How to leverage the well-researched PanelApp knowledgebase to construct your gene lists based on different levels of evidence for a specific disease
How to define gene lists based on the specific phenotypes and disorders you are targeting with your tests
Gathering DATA in the clinical environment. Tommi Lehtonen, Blueprint Genetics.
Gathering DATA in the clinical environment. Tommi Lehtonen, Blueprint Genetics. Upgraded - Health Startup Association of Finland
Presented in Upgraded Life Festival 31.5.2016 by Tommi Lehtonen, Blueprint Genetics. http://www.upgradedlifefestival.com/ V Shyamala CV
This document provides a summary of the work experience and qualifications of Venkatakrishna Shyamala, Ph.D. It outlines her extensive experience in molecular diagnostics and blood testing spanning over 30 years, including roles leading research and development teams at multiple biotech companies. Her areas of expertise include assay development, scientific affairs, and evaluating nucleic acid testing technologies.
Clinical Reporting Made Easy
This webcast will walk through preparing a template for report generation, reviewing the generated report and performing some report customizations.
ppt6
JetBlue has strengths in effective aircraft operations, positioning in New York, and active marketing with low distribution costs. However, it has weaknesses such as high debt obligations, sluggish profits, and low margins. External opportunities include recovery of the US airline industry and benefits to low-cost carriers in a weak economy, but threats include intense price competition, industry consolidation, terrorism, and increased government regulations.
PPT5
My cousin helped me buy my first car after graduating and finding a job. We had an intense negotiation with the dealer that lasted all day before finally agreeing on a price the next morning. The experience taught me lessons about not rushing into big purchases, being influenced by others, and choosing negotiating partners wisely.
PPT2
JetBlue has strengths in effective aircraft operations, strong positioning in the New York metropolitan area, and active marketing with low-cost distribution channels. However, JetBlue also has weaknesses such as high debt and fixed obligations, sluggish profits and margins. External threats include intense competition from low-cost airlines, industry consolidation, terrorism, and increased government regulations. The recovery of the US airline industry works in JetBlue's favor.
PPT1
Peritonitis in patients undergoing peritoneal dialysis is commonly diagnosed based on symptoms of fever, abdominal pain, and nausea, along with lab findings of increased white blood cells over 100 cells/mm3 with neutrophil predominance. Infections are often gram positive or gram negative bacteria but about 20% have no growth on culture. Fungal infections are rare but Candida is the most common cause. Noninfectious complications include GERD, vomiting, electrolyte abnormalities like hypokalemia, and potentially fatal acute mesenteric ischemia.
More Related Content
What's hot
Updates to VSClinical ACMG Guidelines & a Tour of Cancer Annotation Sources
Earlier this year we launched our latest product VSClinical featuring workflow support for the ACMG guidelines with advanced automation capabilities and per-criteria recommendations. It has been amazing to watch the adoption of this product in labs doing both germline and in some cases cancer variant interpretation. Our latest VarSeq 2.1 release demonstrates our approach to iterative product improvements based on our committed relationship with our customers and includes numerous enhancements to VSClinical.
In this webcast, we cover the new and updated capabilities that can add value to your genetic testing workflows as well as review the VarSeq workflow support somatic variant interpretation in tumors by leveraging our cancer-specific annotations sources. In this webcast, we:
-Demonstrate the new “Consortium Classification” support in VSClinical to have an additional ClinVar-like annotation source added to the automated and interactive ACMG scoring process.
-See how previous interpretations are integrated into your VSClinical analysis, whether they are for the current variant or are just in the genomic neighborhood.
-Cover the additional “Lookup in PubMed” variant search feature for finding supporting studies that may provide functional or clinical evidence for a variant.
-See in action the new ACMG Auto Scoring based templates for trio analysis and gene panel tests.
-Review somatic variant filtering and prioritizing in VarSeq and the updates to relevant public annotation sources including CiVIC, ICGC and a new and available to license COSMIC v86!
Liquid biopsies- Learn about the newer ways of diagnosing malignancy
Liquid biopsies are innovative methods of detecting serious conditions at its very onset. It's now in its developmental stage. Some of the liquid biopsies are approved by the FDA of United States and are spreading across the world. Let's hope that this opens the field of easier, earlier and more economic detection of diseases.
PhoRank 2.0: Improved Phenotype-Based Gene Ranking in VarSeq
When performing variant analysis on whole exome or large gene panels, clinicians must sort through thousands of variants to determine which variants are most likely to be associated with the patient’s phenotypes. To assist with this process, we have implemented the PhoRank algorithm, which incorporates phenotypic associations to highlight the most relevant genes with potentially damaging variants. PhoRank 1.0 supports researchers leveraging all possible gene-disease associations by traversing multiple gene and pathway ontologies. Recent papers have demonstrated new techniques that have improved ranking performance in a clinical context. We have incorporated these new strategies into PhoRank 2.0: providing better ranking and improved computational performance for most clinically diagnostic and testing scenarios. Join us in this webinar as we cover:
Utility of gene ranking in genetic testing
Scenarios that warrant the use of PhoRank 2.0
New ranking strategies provided by recent papers
Benchmarks of PhoRank 2.0 on published datasets
Golden Helix provides a comprehensive solution for NGS testing labs to perform best practice guidelines such as ACMG and AMP. Our gene ranking methods provide a vital role in scaling tests to large gene panels and exomes. Please join us as we review the testing workflow and how this significant update to our gene ranking algorithm fits into the testing workflow.
Wu xi apptec lab testing division overview 2016
WuXi AppTec's Laboratory Testing Division is a large growth engine that provides integrated testing solutions to support drug development, clinical diagnostics, and medical device testing. It has over 1,600 employees across sites in China and the US. The division offers a full range of preclinical and clinical services, including CMC development, safety and efficacy testing, bioanalysis, and biomarker analysis. It also has platforms for in vitro diagnostics and medical device testing. The division aims to transform scientific ideas into healthcare products to better serve patients.
Aug2013 GeT-RM project and genome browser
This document summarizes the GeT-RM Project and Browser, which collects and analyzes genetic variant data submitted by various clinical and research laboratories. It describes the project team members and submitting labs. It provides information on the types and platforms of tests conducted, validation methods used by labs, read count distributions, and gene-level concordance calculations. It also outlines future analyses, improvements to the browser, and inclusion of paralogous sequence variant data.
Golden Helix's End-to-End Solution for Clinical Labs
In this webcast, we provide an overview of our complete end-to-end clinical stack. Initially, we walk through our powerful secondary analysis pipeline which allows you to call SNVs and CNVs. We then demonstrate how various types of CNVs are called and discuss metrics that express the confidence associated with each call.
From there, we show you our powerful tertiary analysis capabilities for gene panels, exome, and whole genome data. We show how our users can move seamlessly from the variant interpretation stage to a clinical report. Lastly, we demonstrate how our genetic data warehouse, VSWarehouse, can be used in the clinic. We also demonstrate various use cases and show how a comprehensive assessment catalog can be utilized to ensure consistent analysis across multiple labs.
We hope you enjoy our first presentation on Golden Helix's entire end-to-end solution for clinical labs!
Introducing VSClinical: Streamlining ACMG Variant Interpretation Guidelines
We have seen the widespread adoption of VarSeq in the clinic. It is chosen for its versatility and flexibility as well as the extensive catalog of annotations provided by Golden Helix. In a genetic testing scenario, VarSeq provides the annotated and filtered list of high-quality variants to that are ready for the user to classify and interpret.
In this webcast, we introduce a new product VSClinical that enables the interpretation of variants following the ACMG Guidelines. By incorporating new algorithms and annotation sources, detailed variant scoring and classification can occur right within VarSeq and without the need for additional external tools or resources.
Join us to see these upcoming capabilities:
Streamline the ACMG scoring guidelines with supportive recommendation and incorporated historical precedence
See the new algorithms behind the automated recommendation algorithm, and how they provide various levels of evidence
Drill down to an unprecedented level of supporting evidence for mutation hot spots, splice site predictions, and related clinical assertions
Build your own lab practices around new capabilities of blinded interpretations, collaborative interpretation review and detailed audit logs for CLIA compliance
Finalize your interpretation for a sample and compose the clinical report with the classified variants and their interpretation
In combination, this can be a game-changer for any clinical lab looking to improve their efficiency and reproducibility of the most complex step in the genetic testing workflow.
Introducing Drugs & Trials for Cancer Diagnostics
When interpreting a variant using the AMP/ASCO guidelines for somatic variant interpretation, clinicians must determine whether the variant can be considered a biomarker that affects clinical care by predicting sensitivity, resistance, or toxicity to a specific therapy. Such a determination requires the investigation of multiple evidence sources, including clinical trials, FDA approved therapies and peer-reviewed studies. Unfortunately, strong evidence linking specific genetic biomarkers to FDA-approved therapies only exists for a small number of cancers. Thus, most variants require an exploration of clinical practice guidelines, peer-reviewed literature, and large-scale cancer mutation databases to effectively assess the clinical significance of a given mutation.
This webcast explores this new incorporation of Drugs & Trials Annotations in VSClinical's AMP Workflow covering:
Identification of relevant clinical evidence for drug sensitivity and resistance based on patient biomarkers and tumor type
Review of clinical trial information including inclusion criteria, trial status, and contact information
Management of citations associated with relevant, targeted therapies
Evaluation of a biomarkers clinical evidence tier based on available evidence for drug sensitivity and resistance
Pre-Clinical Strategies for Evaluation and Validation of Percutaneous Heart V...
Pre-Clinical Strategies for Evaluation and Validation of Percutaneous Heart V...marcus evans Network
Chip Corso, Edwards Lifesciences, Speaker at the marcus evans Medical Device R&D Summit Fall 2011, Amelia Island, Florida, delivered his presentation on Pre-Clinical Strategies for Evaluation and Validation of Percutaneous Heart ValvesWhat to Expect During an HRPP Quality Improvement Unit Routine Site Visit : P...
This document discusses preparing for and undergoing a routine site visit from the UCSF HRPP Quality Improvement Unit (QIU). It outlines what studies undergo these visits, how to schedule and prepare records, what to expect during the 3-hour visit, common findings from past visits, and resources for questions. The QIU conducts routine monitoring of studies that are greater than minimal risk and have been active for 5 years or less. Preparing includes assembling regulatory documents, reviewing records using the QIU's form, and addressing any issues found. The visit involves discussion, record review, and feedback on recommendations or significant findings.
ZhenWuCV2016
This document summarizes the qualifications and experience of Zhen Wu, including over 20 years of experience in biomedical research with expertise in biologics drug development and bioanalytical assays. Wu has worked in both the biotechnology/pharmaceutical industry and academia, leading multiple biologics projects involving antibody, fusion protein, and oligonucleotide therapeutics. Wu's experience includes developing and validating bioanalytical assays, managing outsourced studies, conducting preclinical research, and providing support for IND submissions and clinical trials.
Reduce Turn-Around with Enhanced Cancer Annotations and CancerKB Updates
Annotation sources are constantly evolving, sometimes quite literally overnight. This is especially true in the case of cancer databases. These ever-evolving annotation sources, coupled with increasing research publications, make it difficult to do variant analysis with up-to-date scientific knowledge. With the resources available to an individual clinician or single lab, this may even prove impossible. Fortunately, VSClinical provides access to the most current clinical annotation sources - automating scoring and interpreting variants according to the most recent ACMP and AMPO guidelines. This includes many fast-changing sources such as ClinVar and COSMIC, as well as expert-curated reviews of literature and the latest drug-labeling from regulatory bodies.
In this webcast, we demonstrate the automation of a cancer workflow with enhanced cancer annotations for somatic and germline cancer variants:
- Golden Helix’s own CancerKB database has been updated to include new interpretations for genes and biomarkers with AMP Tier Level I evidence for drug sensitivity, resistance, diagnostic, and prognostic information.
- We feature a new Golden Helix curated annotation source that automates the scoring of TP53 variants with the special rule specifications by ClinGen’s TP53 Expert Panel.
- The ClinGen Expert Curated Interpretation of Variants has always been available as an annotation source for VarSeq projects, but now the expert comments and interpretations can automatically be pulled into VSClinical and used for clinical reports.
This webcast walks through a hematological-focused cancer workflow that shows off the enhanced cancer annotations and CancerKB updates!
Processing Hereditary Cancer Panels in VarSeq
Processing variants related to cancer is an incredibly critical process and a primary goal is to not only assess the variants rapidly but also accurately. A major improvement to cancer panel workflow efficiency is to utilize VarSeq for variant filtering, annotating, and interpretation. In this webcast we’ll cover some important quality assurance capabilities VarSeq provides, multiple approaches to build targeted panels, how to access/utilize numerous cancer annotations, and finally work through the ACMG guideline process on the selected germline cancer variants. The overall goal is to cover the basics of building the cancer gene panel project template so that it can be used routinely in high throughput environments.
How to Get Published in a Scientific Journal
Dr. Edward Kai-Hua Chow, JALA Associate Editor/Asia and National University of Singapore, shares his SLAS2013 JALA and JBS Authors Workshop presentation. Learn more about these leading peer-reviewed journals, and then see Ed's tips for publication beginning on slide 16.
Creating & Managing Reusable Gene Lists with VSClinical
Golden Helix supports performing repeatable clinical workflows designed to meet the needs of your lab's clinical genetic tests. A critical component of any genetic test is the reporting of clinically significant genes and the ability to limit interpretations to a predefined set of test-specific genes. This webinar will cover the upcoming “Managed Gene List” feature of VarSeq and VSClinical which enables the defining and re-use of gene lists outside of individual product templates.
The community has stepped up to provide disease-specific gene lists that are validated and well-researched for specific genetic disorders. In this webinar, we will discuss how these gene lists can be incorporated into your VSClinical workflows and we will demonstrate how these gene lists can be modified to meet the specific needs of your lab.
Things you will learn:
How to manage gene lists in a single location and use them for filtering, annotation, and reporting
How to use the recently released ACMG Secondary Findings v3.0 list for reporting incidental findings
How to leverage the well-researched PanelApp knowledgebase to construct your gene lists based on different levels of evidence for a specific disease
How to define gene lists based on the specific phenotypes and disorders you are targeting with your tests
Gathering DATA in the clinical environment. Tommi Lehtonen, Blueprint Genetics.
Gathering DATA in the clinical environment. Tommi Lehtonen, Blueprint Genetics. Upgraded - Health Startup Association of Finland
Presented in Upgraded Life Festival 31.5.2016 by Tommi Lehtonen, Blueprint Genetics. http://www.upgradedlifefestival.com/ V Shyamala CV
This document provides a summary of the work experience and qualifications of Venkatakrishna Shyamala, Ph.D. It outlines her extensive experience in molecular diagnostics and blood testing spanning over 30 years, including roles leading research and development teams at multiple biotech companies. Her areas of expertise include assay development, scientific affairs, and evaluating nucleic acid testing technologies.
Clinical Reporting Made Easy
This webcast will walk through preparing a template for report generation, reviewing the generated report and performing some report customizations.
What's hot (18)
Updates to VSClinical ACMG Guidelines & a Tour of Cancer Annotation Sources
Updates to VSClinical ACMG Guidelines & a Tour of Cancer Annotation Sources
Liquid biopsies- Learn about the newer ways of diagnosing malignancy
Liquid biopsies- Learn about the newer ways of diagnosing malignancy
PhoRank 2.0: Improved Phenotype-Based Gene Ranking in VarSeq
PhoRank 2.0: Improved Phenotype-Based Gene Ranking in VarSeq
Golden Helix's End-to-End Solution for Clinical Labs
Golden Helix's End-to-End Solution for Clinical Labs
Introducing VSClinical: Streamlining ACMG Variant Interpretation Guidelines
Introducing VSClinical: Streamlining ACMG Variant Interpretation Guidelines
Pre-Clinical Strategies for Evaluation and Validation of Percutaneous Heart V...
Pre-Clinical Strategies for Evaluation and Validation of Percutaneous Heart V...
What to Expect During an HRPP Quality Improvement Unit Routine Site Visit : P...
What to Expect During an HRPP Quality Improvement Unit Routine Site Visit : P...
Reduce Turn-Around with Enhanced Cancer Annotations and CancerKB Updates
Reduce Turn-Around with Enhanced Cancer Annotations and CancerKB Updates
Creating & Managing Reusable Gene Lists with VSClinical
Creating & Managing Reusable Gene Lists with VSClinical
Gathering DATA in the clinical environment. Tommi Lehtonen, Blueprint Genetics.
Gathering DATA in the clinical environment. Tommi Lehtonen, Blueprint Genetics.
More from callroom
ppt6
JetBlue has strengths in effective aircraft operations, positioning in New York, and active marketing with low distribution costs. However, it has weaknesses such as high debt obligations, sluggish profits, and low margins. External opportunities include recovery of the US airline industry and benefits to low-cost carriers in a weak economy, but threats include intense price competition, industry consolidation, terrorism, and increased government regulations.
PPT5
My cousin helped me buy my first car after graduating and finding a job. We had an intense negotiation with the dealer that lasted all day before finally agreeing on a price the next morning. The experience taught me lessons about not rushing into big purchases, being influenced by others, and choosing negotiating partners wisely.
PPT2
JetBlue has strengths in effective aircraft operations, strong positioning in the New York metropolitan area, and active marketing with low-cost distribution channels. However, JetBlue also has weaknesses such as high debt and fixed obligations, sluggish profits and margins. External threats include intense competition from low-cost airlines, industry consolidation, terrorism, and increased government regulations. The recovery of the US airline industry works in JetBlue's favor.
PPT1
Peritonitis in patients undergoing peritoneal dialysis is commonly diagnosed based on symptoms of fever, abdominal pain, and nausea, along with lab findings of increased white blood cells over 100 cells/mm3 with neutrophil predominance. Infections are often gram positive or gram negative bacteria but about 20% have no growth on culture. Fungal infections are rare but Candida is the most common cause. Noninfectious complications include GERD, vomiting, electrolyte abnormalities like hypokalemia, and potentially fatal acute mesenteric ischemia.
Test Presentation
The document discusses strategies for foreign market entry, including overcoming liability of foreignness, understanding factors that influence internationalization, and a comprehensive model for foreign market entries. It addresses questions of where, when, and how to enter foreign markets, analyzing location-specific advantages, timing of market entry, and options for entry modes. Key tradeoffs between equity and non-equity entry modes like exports, licensing, and foreign direct investment are also summarized.
Thyroid and the Heart
This document discusses syncope, which is a transient loss of consciousness due to temporary reduced blood flow to the brain. It notes that syncope accounts for around 1% of emergency department visits and is a common cause of hospitalization for those over 65. Establishing the exact cause is difficult as the patient has usually recovered by the time they are examined. The document then discusses various causes of syncope and nonsyncopal attacks that can be mistaken for syncope. It provides breakdowns of common causes by age group and discusses the natural history and risk stratification of syncope of unknown cause in the emergency department.
Myocardial Viability - the STICH Trial NEJM May 2011
This study examined whether testing for myocardial viability can identify patients with coronary artery disease and left ventricular dysfunction who benefit most from coronary artery bypass grafting (CABG) compared to medical therapy alone. Of over 1200 patients enrolled in the main trial, 601 who underwent viability testing by single-photon emission computed tomography (SPECT) or dobutamine echocardiography were included in this substudy. Patients who had viability testing were more likely to have certain risk factors and worse heart function. The study aimed to determine if viability testing could identify which patients would have improved survival rates with CABG versus medical therapy.
Flail Leaflet
This document discusses flail mitral leaflet, which is a cause of mitral regurgitation requiring surgical correction. It occurs when the chordae tendineae connecting the mitral leaflet to the papillary muscles rupture. This causes the mitral leaflet to flail or balloon into the left atrium during systole. If left untreated, it can lead to complications like congestive heart failure, atrial fibrillation, thromboembolism and death. Surgical repair or replacement of the mitral valve is usually required to treat significant flail mitral leaflet.
Fat versus Fit
This study examined the association between cardiorespiratory fitness, adiposity, and mortality in older adults. It found that higher fitness levels were associated with lower mortality rates regardless of body composition. Specifically, even obese individuals had lower mortality if they were fit compared to unfit normal-weight or lean individuals. The study also found a J-shaped relationship between BMI and mortality both before and after adjusting for fitness levels.
Cardiac MR and viability
An 80 year old female with a history of hypertension, hyperlipidemia, diabetes, and prior stroke presented with 2 weeks of continuous chest pain and was found to have a left bundle branch block. Cardiac enzymes were negative. She was transferred to the hospital for further management and evaluation.
Cardiac MR and viability
This document describes a case of an 80 year old female patient with a history of hypertension, hyperlipidemia, diabetes, and prior stroke who presented with 2 weeks of continuous chest pain. She was found to have left bundle branch block of unknown duration on EKG. Cardiac enzymes were negative. The patient was transferred for further cardiac management.
LFT Review
The document discusses several cases presenting with abnormal liver function tests (LFTs). Case 1 shows a mild isolated transaminitis. Case 2 involves severe hepatocellular injury and mild cholestasis in an alcoholic patient. Case 3 examines LFT patterns in an alcoholic cirrhotic with possible alcoholic hepatitis.
testing123
This document summarizes methods for predicting the functional effects of amino acid substitutions, including SIFT (Sorts Intolerant From Tolerant), which uses sequence conservation to predict whether an amino acid substitution will affect protein function. SIFT has similar prediction accuracy to tools using protein structure. Case studies on disease genes like MSHR, PPARα, and MTHFR show SIFT can distinguish pathogenic from benign variants and detect variants under balancing selection. Focusing genetic association studies on predicted functional variants in genes and conserved non-coding regions improves the direct approach to finding disease loci.
Hypertrophic Cardiomyopathy
This document summarizes a 56-year-old African American man who presented to the hospital after an abnormal stress test. He has a history of hypertension and was previously diagnosed with left ventricular hypertrophy. A recent stress test found ventricular tachycardia and imaging showed an apical aneurysm and small inferior wall ischemia. He is currently taking medications for hypertension and has a family history of coronary artery disease.
C. diff presentation
Clostridium difficile infection rates in the US increased from 30-40 per 100,000 in the mid-1990s to 84 per 100,000 in 2005, and in Britain C. diff became the primary cause of an increasing number of deaths from 499 in 1999 to 3393 in 2006. While metronidazole and vancomycin have been the standard treatments since the 1970s, failure rates for metronidazole increased significantly to 18.2% since 2000. Metronidazole is recommended as the first line treatment for mild cases, but vancomycin should be used for more severe infections. The ultimate goal in treating recurrent C. diff infections is to discontinue all antibiotics
test
The document provides an overview and introduction to the key features and functionality of the Android 2.3 mobile operating system. It describes how to perform basic tasks like starting up Android for the first time, getting familiar with the home screen and user interface, managing notifications, using applications and more. The guide is organized by topic, with each section providing details on a different aspect of the Android system like calls, contacts, browsing the web, and changing system settings.
Hemostasis and Thrombosis
This lecture describes the basic pathophysiologic and pharmacologic basis of hemostasis and thrombosis
- A 53-year-old female with a history of breast cancer was admitted for an elective ureteral stent placement due to tumor compression of her left ureter.
- Shortly after the uncomplicated procedure, the patient became hypotensive, hypoxic, and unresponsive. Imaging showed bowel ischemia with pneumatosis and hemoperitoneum.
- Despite pressor support and broad-spectrum antibiotics, the patient's condition deteriorated and she eventually passed away.
The document discusses the use of an intra-aortic balloon pump (IABP), including appropriate timing of inflation in the cardiac cycle, risks of premature or late deflation, and guidelines for weaning a patient from the device. It notes that the IABP has applications in cardiac failure, refractory angina, cardiogenic shock, and as a bridge to transplantation. Risks include limb ischemia, thrombosis, emboli, bleeding, and aortic complications. Weaning should occur over 24-48 hours with decreasing inotropic support and pump ratios monitored closely.
More from callroom (20)
Myocardial Viability - the STICH Trial NEJM May 2011
Myocardial Viability - the STICH Trial NEJM May 2011
Recently uploaded
pathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathology
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
It includes regulation of combination products and medical devices. FDA and industry liaisons.
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.Cell Therapy Expansion and Challenges in Autoimmune Disease
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
share - Lions, tigers, AI and health misinformation, oh my!.pptx
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
Top Travel Vaccinations in Manchester
Travel vaccination in Manchester offers comprehensive immunization services for individuals planning international trips. Expert healthcare providers administer vaccines tailored to your destination, ensuring you stay protected against various diseases. Conveniently located clinics and flexible appointment options make it easy to get the necessary shots before your journey. Stay healthy and travel with confidence by getting vaccinated in Manchester. Visit us: www.nxhealthcare.co.uk
All info about Diabetes and how to control it.
One health condition that is becoming more common day by day is diabetes.
According to research conducted by the National Family Health Survey of India, diabetic cases show a projection which might increase to 10.4% by 2030.
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
In some case, your chronic prostatitis may be related to over-masturbation. Generally, natural medicine Diuretic and Anti-inflammatory Pill can help mee get a cure.
Histopathology of Rheumatoid Arthritis: Visual treat
Histopathology of Rheumatoid Arthritis: Visual treat
Recently uploaded (20)
pathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathology
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Histopathology of Rheumatoid Arthritis: Visual treat
Histopathology of Rheumatoid Arthritis: Visual treat
Test PPT
- 1. Project Requirement SOPs Biospecimen Research Standards Development Public Products Large Scale Projects Scientific Standards Standardized Reference Sets Clinical Trials Correlative Studies Rare Disease Limited Donor Pool caHUB Customer Type Fulfillment NCI/NIH Advocacy Groups Academia Industry Other Gov’t Benchmark Biospecimen Collection caHUB Customer Delivery Organ Transplant Specimen Processing & Quality Control Specimen Processing & Quality Control Informatics Hospital Organ Transplant Rapid Autopsy Hospital Informatics Hospital Rapid Autopsy Hospital